<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): April 10, 2000
LJL BIOSYSTEMS, INC.
(Exact name of registrant as specified in its charter)
000-23647
(Commission File Number)
DELAWARE 77-0360183
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation)
405 TASMAN DRIVE
SUNNYVALE, CA 94089
(Address of principal executive offices, with zip code)
(408) 541-8787
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
<PAGE>
ITEM 5. OTHER EVENTS.
On April 10, 2000, LJL BioSystems, Inc. announced that in light of
current market conditions, it would not proceed with its proposed follow-on
public offering. Further details regarding this announcement are contained in
the company's news release dated April 10, 2000 attached as an exhibit hereto
and incorporated herein by reference.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND
EXHIBITS
(a) Exhibits:
99.15 LJL BioSystems, Inc. News Release dated April 10, 2000
-2-
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
LJL BIOSYSTEMS, INC.
Date: April 10, 2000 By: /s/ Lev J. Leytes
------------------------------------
Lev J. Leytes
President and CEO
-3-
<PAGE>
Exhibit 99.15
FOR IMMEDIATE RELEASE
LJL BIOSYSTEMS WITHDRAWS FOLLOW-ON PUBLIC OFFERING
SUNNYVALE, Calif.--(BUSINESS WIRE)--April 10, 2000--LJL Biosystems, Inc.
(Nasdaq: LJLB) announced today that in light of current market conditions, it
would not proceed with its proposed follow-on public offering. On Tuesday
March 14, 2000, LJL Biosystems filed a registration statement with the
Securities and Exchange Commission relating to a proposed public offering of
2,875,000 shares of common stock. LJL Biosystems will file an application
with the Securities and Exchange Commission to withdraw the filing of the
registration statement.
About LJL BioSystems, Inc.
LJL BioSystems designs, produces and sells infrastructure tools that
accelerate and enhance the process of discovering new drugs in the genomics
and post-genomics era. Our products, including instruments and consumables,
are designed to provide flexible, cost-efficient, high throughput solutions
that can be used across all stages of the drug discovery process, including
screening and genotyping. Our worldwide customers include pharmaceutical,
biotechnology and genomics companies as well as research institutions. LJL's
customers include, among others, AstraZeneca, Aventis, Bristol Myers Squibb,
SmithKline Beecham, Eli Lilly, Pfizer, Merck, Johnson and Johnson, Tularik,
Millennium Pharmaceuticals, Amgen, and Incyte. LJL is headquartered in
Sunnyvale, California and has a subsidiary in the United Kingdom. Additional
information can be found at www.ljlbio.com.
Forward-Looking Statements
Statements made in this news release, other than statements of historical
fact, are forward-looking statements within the meaning of Section 21E of the
Securities Exchange Act, including statements regarding LJL's "expectations",
"goals", "beliefs", "hopes", "designs", "intentions", "strategies" or the
like. Such statements are subject to risks and uncertainties that could cause
actual results to differ materially, including such factors, among others, as
the impact of competitive products and pricing, the timely development and
market acceptance of new products, the ability to raise capital,
concentration of HTS and Ultra-HTS markets, market conditions, the mix
between domestic and international sales, manufacturing and cost of LJL's
products, dependence on collaborative partners, the enforcement of
intellectual property rights, and uncertainties relating to sole source
suppliers, technological approaches, FDA and other regulatory approvals.
These and other risk factors are discussed in LJL's Annual Report on Form
10-K, filed February 16, 2000, and its Registration Statement on Form S-3
filed on March 14, 2000 (see, in particular, Risk Factors and Management's
Discussion and Analysis of Financial Condition and Results of Operations).
LJL disclaims any intent or obligation to update these forward-looking
statements. As a result of these and other factors, LJL expects to experience
-4-
<PAGE>
significant fluctuations in operating results, and there can be no assurance
that LJL will become or remain consistently profitable in the future.
For information on LJL BioSystems, Inc., contact Larry Tannenbaum, Chief
Financial Officer, at 408-548-0542 or [email protected].
CONTACT: LJL BioSystems, Inc:
Larry Tannenbaum, 408/548-0542
[email protected]
or
Friestedt International
Susanne Friestedt, 619/223-8844
[email protected]
-5-
